FDA chief frames biosimilar insulin as answer to 'intolerable' prices 15-May-2019 By Nick Taylor Acting US FDA commissioner thinks incoming changes to the regulation of insulin may counter the ‘whopping’ price increases seen in recent years.
Lilly cuts insulin price 50% after congressional hearing 06-Mar-2019 By Ben Hargreaves Lilly announces the launch of a generic version of Humalog, which will be available in the US with a list price 50% lower than the brand product.
